On April 21, 2025, Japan Vietnam Medical Investment and Development Joint Stock Company (JVC) successfully held its 2025 Annual General Meeting of Shareholders (AGM) at the 8th Floor Conference Hall, VNCC Building, 243 De La Thanh Street, Lang Thuong Ward, Dong Da District, Hanoi.

At the meeting, Mr. Pham Thanh Nam – Vice Chairman of the Board of Directors and Chief Executive Officer – presented the Company’s 2024 performance report. 2024 marked the third consecutive year JVC implemented the OKRs (Objectives and Key Results) management framework, while continuing to build a people-centric corporate culture under the spirit: “JVC people – cheerful, friendly, and cooperative.” The company’s direction throughout 2024 was defined by the motto: “Transformation – Speed – Breakthrough,” which enabled JVC to adapt flexibly to market challenges and sustain its growth momentum.

Despite facing intense competition in the medical equipment and supplies market—an industry heavily influenced by complex regulatory policies, slow disbursement processes, and strict bidding regulations—JVC, under the leadership of the Board of Directors and the perseverance of the Executive Board and all staff members, achieved notable results in both revenue and profit:

• Net revenue in 2024: VND 611.67 billion, reaching approximately 115.2% of the 2024 AGM target.

• Net profit after tax in 2024: VND 40.2 billion – affirming the efficiency of the company’s management and operations.

The AGM also approved the strategic direction for 2025, in which JVC aims to maintain strong growth in its trading segment by focusing on pioneering, high-tech products to achieve breakthrough results in revenue and performance. Currently, the company is negotiating with several major manufacturers to distribute high-value products such as medical robots and Digital Subtraction Angiography (DSA) systems.

In addition, starting from 2025, the company plans to prioritize investments in hospitals, medical services, and public-private partnership (PPP) projects to ensure long-term efficiency and sustainable growth.

Based on the strategic orientation and its existing foundational advantages, JVC’s Board of Directors and Executive Board have set the following 2025 business targets:

• Consolidated revenue: VND 1,200 billion

• Consolidated net profit after tax: VND 100 billion

Key Resolutions Approved at the AGM:

• Approval of the 2024 performance report and 2025 business plan of the Board of Directors and the Executive Board of Japan Vietnam Medical Investment and Development Joint Stock Company (“the Company”).

• Approval of the 2024 Supervisory Board's activity report.

• Approval of the audited 2024 Financial Statements of the Company (as detailed in Proposal No. 01/2025/TTr-BOD dated March 31, 2025).

• Approval of the list of independent auditing firms for auditing the Company’s 2025 Financial Statements (as detailed in Proposal No. 02/2025/TTr-SB dated March 31, 2025).

• Approval of the 2024 profit distribution plan (as detailed in Proposal No. 03/2025/TTr-BOD dated March 31, 2025).

• Approval of the 2024 remuneration for the Board of Directors and Supervisory Board, and the 2025 remuneration plan (as detailed in Proposal No. 03/2025/TTr-BOD dated March 31, 2025).

• Approval to continue implementing the private share issuance plan and to amend and supplement certain contents of the issuance plan (as detailed in Proposal No. 04/2025/TTr-BOD dated March 31, 2025).

• Approval of several general matters within the authority of the General Meeting of Shareholders (as detailed in Proposal No. 06/2025/TTr-BOD dated March 31, 2025).

• Approval of changes in the number and titles of the Company’s legal representatives, and amendments to the Company’s Charter (as detailed in Proposal No. 07/2025/TTr-BOD dated April 18, 2025).

• Approval of the dismissal of Mr. Nguyen Hai Ha from the Board of Directors, effective April 21, 2025.

• Approval of the dismissal of Mr. Nguyen Van Vy and Ms. Nguyen Thi Tien Chi from the Supervisory Board, effective April 21, 2025.

• Approval of the election of Mr./Ms. Vu Khanh Din as a member of the Board of Directors for the 2021–2026 term.

• Approval of the election of Mr. Do Duc Hiep and Ms. Nguyen Vu Y Tan as members of the Supervisory Board for the 2021–2026 term.